Will Multaq fly in antiarrhythmic market with removal of insurance standard condition?
The Sanofi’s antiarrhythmic drug ‘Multaq(generic name: dronedarone)’ seems to be easy on its usage in the clinical field due to relaxation of the health insurance standard.
The Ministry of Health and Welfare(MOHW) gave an administrative notice of the ‘Amendment to the Details on Health Insurance...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
